Strategies in cell-free tissue-engineered vascular grafts
Related Experiment Video
Updated: Jan 5, 2026
Generation and Grafting of Tissue-engineered Vessels in a Mouse Model
Published on: March 18, 2015
Haoyong Yuan1, Chunyang Chen1, Yuhong Liu1
1Department of Cardiovascular surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Insights
Tissue-engineered vascular grafts (TEVGs) offer alternatives for coronary artery bypass grafting when autologous grafts fail. Cell-free TEVG strategies promote in situ regeneration, potentially leading to off-the-shelf vascular solutions.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Cardiovascular Surgery
Background:
- Cardiovascular diseases (CVD), particularly coronary artery diseases (CAD), are leading global health concerns.
- Coronary artery bypass grafting (CABG) is a primary treatment, but limitations exist when autologous grafts are unavailable.
- Tissue-engineered vascular grafts (TEVGs) are being developed as alternatives, with recent focus shifting from cell-based to cell-free strategies.
Purpose of the Study:
- To review manufacturing strategies for cell-free tissue-engineered vascular grafts (TEVGs).
- To discuss materials, functionalization methods, and challenges in TEVG development.
- To explore the future prospects of cell-free TEVGs for clinical application.
Main Methods:
- Review of existing literature on TEVG fabrication and functionalization.
- Analysis of cell-free strategies utilizing biomaterials and bioactive molecules.
- Discussion of challenges and future directions in TEVG research.
Main Results:
- Cell-free TEVG strategies show promise for in situ vascular regeneration by recruiting host cells.
- Functionalization with bioactive molecules enhances regeneration and potential for off-the-shelf availability.
- Limitations of previous cell-based strategies are being overcome by cell-free approaches.
Conclusions:
- Cell-free TEVGs represent a significant advancement in regenerative medicine for cardiovascular applications.
- These grafts have the potential to address the unmet need for vascular substitutes in CABG.
- Further research into TEVG design and functionalization is crucial for clinical translation.
Abstract:
Cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality in the world, among which coronary artery diseases (CAD) are the most common type of CVD. Coronary artery bypass grafting (CABG) using autologous vein and artery grafts is the typical surgical intervention for CAD patients. However, for patients whose autologous grafts are not available, there are no appropriate substitutes for vascular grafts. Investigation of tissue-engineered vascular graft (TEVG) has persisted over decades with significant advancement, utilizing different types of biomaterials. In the past two decades, a great number of studies based on cell-seeding strategies were reported. However, limitations of cell-based strategies made clinical application difficult. With the understanding of stem cells and tissue remodeling process, strategies without cell-seeding emerged as potential methods to achieve in situ regeneration. A cell-free graft may recruit host cells and guide their participation in vascular remodeling. The grafts modified by bio-active molecules showed good results in promoting in situ regeneration and exhibited potential to make the vascular grafts off-the-shelf. In this review, the strategies for cell-free TEVG manufacturing were discussed, including the materials for fabricating TEVGs, the methods of functionalization to promote in situ regeneration, the challenges researchers faced in TEVG investigation, and finally the prospects in TEVG design.
